452 related articles for article (PubMed ID: 31126694)
1. Tolerability and Pharmacokinetics of Contezolid at Therapeutic and Supratherapeutic Doses in Healthy Chinese Subjects, and Assessment of Contezolid Dosing Regimens Based on Pharmacokinetic/Pharmacodynamic Analysis.
Wu J; Wu H; Wang Y; Chen Y; Guo B; Cao G; Wu X; Yu J; Wu J; Zhu D; Guo Y; Yuan H; Hu F; Zhang J
Clin Ther; 2019 Jun; 41(6):1164-1174.e4. PubMed ID: 31126694
[TBL] [Abstract][Full Text] [Related]
2. Population Pharmacokinetics Study of Contezolid (MRX-I), a Novel Oxazolidinone Antibacterial Agent, in Chinese Patients.
Li L; Wu H; Chen Y; Yuan H; Wu J; Wu X; Zhang Y; Cao G; Guo B; Wu J; Zhao M; Zhang J
Clin Ther; 2020 May; 42(5):818-829. PubMed ID: 32389326
[TBL] [Abstract][Full Text] [Related]
3. Short-term Safety, Tolerability, and Pharmacokinetics of MRX-I, an Oxazolidinone Antibacterial Agent, in Healthy Chinese Subjects.
Wu X; Li Y; Zhang J; Zhang Y; Yu J; Cao G; Chen Y; Guo B; Shi Y; Huang J; Cao Y; Liu X; Wu J; Gordeev MF; Yuan H; Wang W
Clin Ther; 2018 Feb; 40(2):322-332.e5. PubMed ID: 29398160
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetic rationale for intravenous contezolid acefosamil followed by oral contezolid dosage regimens.
Bulitta JB; Fang E; Stryjewski ME; Wang W; Atiee GJ; Stark JG; Hafkin B
Antimicrob Agents Chemother; 2024 Apr; 68(4):e0140023. PubMed ID: 38415667
[TBL] [Abstract][Full Text] [Related]
5. A phase I study of the safety, tolerability, and pharmacokinetics of contezolid acefosamil after intravenous and oral administration in healthy Chinese subjects.
Yang H; Jin Y; Wang H; Yuan H; Wang J; Li S; Hu Y; Yang H; Li X; Liang H; Wu J; Cao G; Zhang J
Antimicrob Agents Chemother; 2023 Nov; 67(11):e0079623. PubMed ID: 37902402
[TBL] [Abstract][Full Text] [Related]
6. Dose adjustment not required for contezolid in patients with moderate hepatic impairment based on pharmacokinetic/pharmacodynamic analysis.
Wu J; Yang X; Wu J; Wang J; Wu H; Wang Y; Yuan H; Yang H; Wang H; Zhang J
Front Pharmacol; 2023; 14():1135007. PubMed ID: 36992830
[No Abstract] [Full Text] [Related]
7. Evaluation of the Effect of Contezolid (MRX-I) on the Corrected QT Interval in a Randomized, Double-Blind, Placebo- and Positive-Controlled Crossover Study in Healthy Chinese Volunteers.
Wu J; Cao G; Wu H; Chen Y; Guo B; Wu X; Yu J; Ni K; Qian J; Wang L; Wu J; Wang Y; Yuan H; Zhang J; Xi Y
Antimicrob Agents Chemother; 2020 May; 64(6):. PubMed ID: 32229495
[TBL] [Abstract][Full Text] [Related]
8. Single- and Multiple-Dose Study To Determine the Safety, Tolerability, Pharmacokinetics, and Food Effect of Oral MRX-I versus Linezolid in Healthy Adult Subjects.
Eckburg PB; Ge Y; Hafkin B
Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167545
[TBL] [Abstract][Full Text] [Related]
9. Development and validation of ultra-performance liquid chromatography-tandem mass spectrometric methods for simultaneous and rapid determination of contezolid and its major metabolite M2 in plasma and urine samples and its application to a study in subjects with moderate liver impairment.
Wang Y; Wu H; Wu J; Fan Y; Liu X; Li Y; Hu J; Zhang J; Guo B
J Chromatogr B Analyt Technol Biomed Life Sci; 2022 Feb; 1191():123129. PubMed ID: 35066246
[TBL] [Abstract][Full Text] [Related]
10. Determining optimal dosing regimen of oral administration of dicloxacillin using Monte Carlo simulation.
Yu W; Ji J; Xiao T; Ying C; Fang J; Shen P; Xiao Y
Drug Des Devel Ther; 2017; 11():1951-1956. PubMed ID: 28721014
[TBL] [Abstract][Full Text] [Related]
11. Clinical Pharmacology and Utility of Contezolid in Chinese Patients with Complicated Skin and Soft-Tissue Infections.
Yuan H; Wu H; Zhang Y; Huang H; Li Y; Wu J; Cao G; Yu J; Guo B; Wu J; Yuan Z; Chen Y; Yang W; Wu X; Zhang J
Antimicrob Agents Chemother; 2022 Jun; 66(6):e0243021. PubMed ID: 35575579
[TBL] [Abstract][Full Text] [Related]
12. Single-dose Intravenous Safety, Tolerability, and Pharmacokinetics and Absolute Bioavailability of LCB01-0371.
Cho YS; Lim HS; Han S; Yoon SK; Kim H; Cho YL; Nam HS; Bae KS
Clin Ther; 2019 Jan; 41(1):92-106. PubMed ID: 30559004
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and Pharmacodynamics of Levornidazole in Patients With Intra-abdominal AnaerobicInfection.
Wu H; Xie S; Yu J; Chen Y; Wu J; Guo B; Zhu Z; Zhou Y; Wang Z; Zhang J
Clin Ther; 2018 Sep; 40(9):1548-1555. PubMed ID: 30146271
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic/pharmacodynamic target attainment analyses to support intravenous and oral lefamulin dose selection for the treatment of patients with community-acquired bacterial pneumonia.
Bhavnani SM; Zhang L; Hammel JP; Rubino CM; Bader JC; Sader HS; Gelone SP; Wicha WW; Ambrose PG
J Antimicrob Chemother; 2019 Apr; 74(Suppl 3):iii35-iii41. PubMed ID: 30949705
[TBL] [Abstract][Full Text] [Related]
15. Developments in the pharmacokinetic/pharmacodynamic index of linezolid: a step toward dose optimization using Monte Carlo simulation in critically ill patients.
Dong H; Xie J; Chen L; Wang T; Sun J; Zhao Y; Dong Y
Int J Infect Dis; 2014 May; 22():35-40. PubMed ID: 24603161
[TBL] [Abstract][Full Text] [Related]
16. Safety and clinical pharmacokinetics of nemonoxacin, a novel non-fluorinated quinolone, in healthy Chinese volunteers following single and multiple oral doses.
Guo B; Wu X; Zhang Y; Shi Y; Yu J; Cao G; Zhang J
Clin Drug Investig; 2012 Jul; 32(7):475-86. PubMed ID: 22650326
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics, Safety, and Tolerability of Tedizolid Phosphate After Single-dose Administration in Healthy Korean Male Subjects.
Kim Y; Kim A; Lee S; Choi SH; Lee DY; Song JS; Lee H; Jang IJ; Yu KS
Clin Ther; 2017 Sep; 39(9):1849-1857. PubMed ID: 28865799
[TBL] [Abstract][Full Text] [Related]
18.
Carvalhaes CG; Duncan LR; Wang W; Sader HS
Antimicrob Agents Chemother; 2020 Oct; 64(11):. PubMed ID: 32778552
[TBL] [Abstract][Full Text] [Related]
19. A Phase III multicentre, randomized, double-blind trial to evaluate the efficacy and safety of oral contezolid versus linezolid in adults with complicated skin and soft tissue infections.
Zhao X; Huang H; Yuan H; Yuan Z; Zhang Y
J Antimicrob Chemother; 2022 May; 77(6):1762-1769. PubMed ID: 35265985
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetics of levornidazole in healthy subjects and patients, and sequential dosing regimen proposal using pharmacokinetic/pharmacodynamic analysis.
Cao Y; Li Y; Guo B; Zhang J; Wu X; Yu J; Cao G; Fan Y; Wu H
Int J Antimicrob Agents; 2023 Apr; 61(4):106754. PubMed ID: 36773938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
